Nuveen
SMMT icon

Nuveen’s Summit Therapeutics SMMT Stock Holding History

Nuveen’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.3M Buy
294,867
+50,875
+21% +$902K ﹤0.01% 2181
2026
Q1 		$4.63M Buy
243,992
+11,350
+5% +$184K ﹤0.01% 1920
2025
Q4 		$4.07M Hold
232,642
– – ﹤0.01% 1999
2025
Q3 		$4.81M Buy
232,642
+52,193
+29% +$1.27M ﹤0.01% 1919
2025
Q2 		$3.84M Sell
180,449
-55,444
-24% -$1.26M ﹤0.01% 2014
2025
Q1 		$4.55M Buy
235,893
+1,467
+0.6% +$29.4K ﹤0.01% 1970
2024
Q4 		$4.18M Sell
234,426
-35,329
-13% -$685K ﹤0.01% 2065
2024
Q3 		$5.91M Sell
269,755
-6,937
-3% -$97K ﹤0.01% 1910
2024
Q2 		$2.16M Sell
276,692
-93,233
-25% -$504K ﹤0.01% 2350
2024
Q1 		$1.53M Sell
369,925
-195,699
-35% -$778K ﹤0.01% 2518
2023
Q4 		$1.48M Buy
565,624
+175,877
+45% +$362K ﹤0.01% 2552
2023
Q3 		$729K Hold
389,747
– – ﹤0.01% 2703
2023
Q2 		$978K Buy
+389,747
New +$711K ﹤0.01% 2673
2022
Q2 		– Sell
-54,748
Closed -$178K – 3456
2022
Q1 		$178K Sell
54,748
-11,295
-17% -$28.5K ﹤0.01% 3207
2021
Q4 		$303K Sell
66,043
-8,876
-12% -$42.7K ﹤0.01% 3176
2021
Q3 		$478K Buy
74,919
+27,422
+58% +$197K ﹤0.01% 3175
2021
Q2 		$354K Buy
+47,497
New +$312K ﹤0.01% 3205

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Nuveen's SMMT Position: Q2 2026 in Review

Nuveen increased its Summit Therapeutics (SMMT) stake by 21% in Q2 2026, buying an estimated $902K and bringing the position to 294,867 shares worth $4.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

Nuveen first reported a position in SMMT in Q2 2021 and has held it in 17 quarters since. The position peaked at $5.91M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Nuveen held 294,867 shares of Summit Therapeutics worth $4.3M as of Q2 2026.
  • Nuveen bought 50,875 Summit Therapeutics shares in Q2 2026, an estimated $902K.
  • Summit Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2181 holding.
  • Nuveen first reported a position in Summit Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Nuveen's Summit Therapeutics position peaked at $5.91M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.